What type of study is this?

This is a Animal Study study (also classified as: In Vitro Study).

What question did this study set out to answer?

This research aims to explore the effects of direct RAS inhibition on JAK2 inhibition in myeloproliferative neoplasms.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

This research aims to explore the effects of direct RAS inhibition on JAK2 inhibition in myeloproliferative neoplasms.
Used the RAS(ON) multi-selective inhibitor RMC-7977 and JAK2 inhibitor ruxolitinib in preclinical models.
Assessed effects on active ERK levels, growth, and survival of MPN model cells.
Examined combinations in an MPN mouse model driven by MPL-W515L.
RMC-7977 effectively inhibited active ERK levels in MPN cell models.
Combination therapy with RMC-7977 and ruxolitinib showed enhanced growth inhibition beyond either drug alone.
Treatment improved survival rates and suppressed MPN phenotypes, including leukocytosis and hepatosplenomegaly.

No takes yet. Share an insight, caveat, or question.

Preclinical studies show direct RAS inhibition improves outcomes in MPN, indicating enhanced efficacy of JAK2 inhibitor ruxolitinib.

Pandey et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark